and Mihara and Fujimoto (3). In this study, [3H]-(+)-PN200 110 specific binding was competitively displaced by the two enantiomers in depolarized cerebral microvessels. The calculated K; values for S-312-d and S-312-1 were 0.12 and 2.4 nM, respectively. The antihypertensive effect of S-312-d in spontaneously hypertensive rats (SHR) was approximately 100 times stronger than that of S-312-1(4). In addition, a strong prophylactic effect on the occurrence of strokes in stroke prone SHR (SHRSP) and moderate therapeutic effects in diseased SHRSP were also observed by the daily oral administration of S-312-d (5). In these studies, the viability of the pyramidal cells in the hippo campus of surviving SHRSP was significantly increased by S-312-d. S-312-d seems to prevent the occurrence of cell death following a cerebral stroke by its calcium antagonistic effect. Since S-312-d seems to easily pass through the blood brain barrier because of its high lipophilicity (log P = 5.2, n-octanol/water), it should modify some physiological events related to the central nervous system. The present study examined the anticon vulsant effects of S-312-d in several convulsion models in mice.
Using the cerebral microvessels of rats, Dessy et al. (1) further characterized the calcium antagonistic effects of the enantiomers of S-312, methyl 4,7-dihydro-3-isobutyl 6-methyl-4-(3-nitrophenyl)thieno-(2, 3-b)-pyridine-5-car boxylate, following the studies of Ninomiya et al. (2) and Mihara and Fujimoto (3) . In this study, [3H]-(+)-PN200 110 specific binding was competitively displaced by the two enantiomers in depolarized cerebral microvessels. The calculated K; values for S-312-d and S-312-1 were 0.12 and 2.4 nM, respectively. The antihypertensive effect of S-312-d in spontaneously hypertensive rats (SHR) was approximately 100 times stronger than that of S-312-1(4). In addition, a strong prophylactic effect on the occurrence of strokes in stroke prone SHR (SHRSP) and moderate therapeutic effects in diseased SHRSP were also observed by the daily oral administration of S-312-d (5) . In these studies, the viability of the pyramidal cells in the hippo campus of surviving SHRSP was significantly increased by S-312-d. S-312-d seems to prevent the occurrence of cell death following a cerebral stroke by its calcium antagonistic effect. Since S-312-d seems to easily pass through the blood brain barrier because of its high lipophilicity (log P = 5.2, n-octanol/water), it should modify some physiological events related to the central nervous system. The present study examined the anticon vulsant effects of S-312-d in several convulsion models in mice.
Male and female DBA/2 mice 3 weeks after birth at Aburahi and weighing 7 to 11 g were used in the experi ments. Each group consisted of 5 male and 5 female mice. Audiogenic stimulation (70-90 db) caused by an ultrason ic cleaner (B-32; Bronson, Danbury, CT, USA) was applied to each mouse for 1 min at 1 hr after the oral administration of the test compounds. Usually, following a wild running phase, generalized myoclonus and then tonic flexion and extension of mice were caused by an auditory stimulation. Respiratory arrest of mice was observed after the occur rence of tonic extension. The anticonvulsant effect was de termined by recording the tonic extension. ED50 values were calculated by the probit method. Anticonvulsant effects of S-312, S-312-d, S-312-1, nimodipine, nicardipine and nilvadipine, which were synthesized at Shionogi Research Laboratories, were compared with those of flun arizine (Sigma, St. Louis, MO, USA). S-312 and S-312-d, but not S-312-1, had anticonvulsant effects in DBA/2 mice. Dose-dependent anticonvulsant effects were ob served after the oral administration of S-312, S-312-d, nil vadipine and flunarizine (Fig. 1) . Table 1 shows the ED50 values of these drugs.
To observe the anticonvulsant effects on drug-induced or electroshock convulsions in mice, 10 male Slc:ddY mice (Japan SLC, Inc., Hamamatsu), 4 to 6 weeks after birth, were used as one group. One hour after the oral administration of the test compounds, pentylenetetrazole Although almost no anticonvulsant effects were ob served with nicardipine or nimodipine, dose-dependent anticonvulsant effects against the audiogenic convulsion in DBA/2 mice were observed with the oral administra tion of S-312, S-312-d, nilvadipine and flunarizine. Since S-312-1 had no anticonvulsant effect and S-312-d had a stronger effect than S-312, the racemate, these anticon vulsant effects seem to be derived from their calcium an tagonistic effects. Comparing the anticonvulsant effects of various calcium antagonists against the audiogenic convul sion in DBA/2 mice, De Sarro et al. (6) observed that the anticonvulsant effect of flunarizine was several times stronger than that of some dihydropyridine calcium an tagonists such as nicardipine, nimodipine, nifedipine and nitrendipine. Although the anticonvulsant effect against the drug-induced or electro-shock convulsions was weak, the anticonvulsant effects of S-312-d on the audiogenic convulsions in DBA/2 mice were stronger than those of flunarizine. Jones et al. (7) suggested the activation of the glutamatergic system in the audiogenic convulsions in DBA/2 mice, because these convulsions were inhibited by a phosphonate dipeptide. Although S-312-d could not in hibit the drug-induced convulsions caused by the direct ac tivation of the respective nerve receptors, it might be able to suppress the audiogenic convulsions by the inhibition of the massive release of glutamate upon audiogenic stimulation. Recently, Gemba et al. (8) found that S-312 d has marked neuronal protective effects against ischemic injury in SHRSP by the inhibition of massive releases of glutamate. It is also interesting to note that S-312-d dose dependently suppressed the tonic convulsion in sponta neously epileptic rats (9) . Recently, Sasa et al. (10) observed that treatment with repeated oral administration of S 312-d was more effective in inhibiting this convulsion. are also highly appreciated.
